{"title":"晚期肺癌中可溶性PD-L1和PD-1表达特征及其与免疫状态和预后的关系","authors":"Ran Li, Hongge Liang, Ying Shang, Zhengwu Yang, Keqiang Wang, Donghong Yang, Jing Bao, Wen Xi, Dexun Zhou, Wentao Ni, Zhancheng Gao, Xinlin Mu","doi":"10.1111/ajco.14145","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Our study aims to evaluate the characteristics of serum soluble PD-1 (sPD-1) and soluble PD-L1 (sPD-L1) levels and their correlations with immune status and prognosis in advanced lung cancer patients.</p><p><strong>Methods: </strong>Patients diagnosed with advanced lung cancer based on histology or cytology in Peking University People's Hospital from July 2020 to November 2021 were enrolled. Clinicopathological data were recorded and analyzed. Treatment efficacy was evaluated according to RESIST 1.1 criteria. The serum levels of sPD-L1 and sPD-1 were detected by enzyme-linked immunosorbent assay (ELISA). Lymphocyte subsets were measured by flow cytometry to evaluate the immune status of the patients.</p><p><strong>Results: </strong>A total of 65 patients with advanced lung cancer were enrolled. sPD-L1 level in lung cancer patients (15.67 ± 11.09 pg/mL, p = 0.001) was significantly higher than those in healthy controls (5.21 ± 4.46 pg/mL). sPD-1 level did not show a significant difference between patients with lung cancer and healthy controls. sPD-L1 level in patients with progressive disease (PD) was significantly higher than those with partial response (PR) (20.94 ± 8.91 vs. 13.14 ± 12.66 pg/mL, p = 0.033). In treatment-naïve patients, sPD-L1 level was negatively correlated with the lymphocyte ratio (correlation coefficient = -0.452, p = 0.014). Kaplan-Meier survival analysis showed that patients with low sPD-L1 level had a significantly longer progression-free survival (PFS) (10.4 vs. 5.7 months, p = 0.023). However, sPD-1 level did not correlate with lymphocyte subsets or prognosis in overall patients with lung cancer. Subgroup analysis showed that prolonged PFS in patients with low sPD-L1 level was exclusively shown in the NSCLC subgroup, not in the SCLC subgroup. In the subgroups of patients who subsequently received immunotherapy, low sPD-L1 level was correlated with longer PFS in the overall patients and NSCLC patients, and low sPD-1 level was correlated with longer PFS exclusively in NSCLC patients.</p><p><strong>Conclusion: </strong>Serum sPD-L1 level was higher in patients with advanced lung cancer than healthy individuals, which was negatively correlated with the proportion of lymphocytes and prognosis. Serum sPD-1 level did not show significant difference between patients with lung cancer and healthy individuals, which showed no correlation with lymphocyte subsets and the prognosis of overall patients, except NSCLC patients receiving immunotherapy.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Characteristics of Soluble PD-L1 and PD-1 Expression and Their Correlations With Immune Status and Prognosis in Advanced Lung Cancer.\",\"authors\":\"Ran Li, Hongge Liang, Ying Shang, Zhengwu Yang, Keqiang Wang, Donghong Yang, Jing Bao, Wen Xi, Dexun Zhou, Wentao Ni, Zhancheng Gao, Xinlin Mu\",\"doi\":\"10.1111/ajco.14145\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Our study aims to evaluate the characteristics of serum soluble PD-1 (sPD-1) and soluble PD-L1 (sPD-L1) levels and their correlations with immune status and prognosis in advanced lung cancer patients.</p><p><strong>Methods: </strong>Patients diagnosed with advanced lung cancer based on histology or cytology in Peking University People's Hospital from July 2020 to November 2021 were enrolled. Clinicopathological data were recorded and analyzed. Treatment efficacy was evaluated according to RESIST 1.1 criteria. The serum levels of sPD-L1 and sPD-1 were detected by enzyme-linked immunosorbent assay (ELISA). Lymphocyte subsets were measured by flow cytometry to evaluate the immune status of the patients.</p><p><strong>Results: </strong>A total of 65 patients with advanced lung cancer were enrolled. sPD-L1 level in lung cancer patients (15.67 ± 11.09 pg/mL, p = 0.001) was significantly higher than those in healthy controls (5.21 ± 4.46 pg/mL). sPD-1 level did not show a significant difference between patients with lung cancer and healthy controls. sPD-L1 level in patients with progressive disease (PD) was significantly higher than those with partial response (PR) (20.94 ± 8.91 vs. 13.14 ± 12.66 pg/mL, p = 0.033). In treatment-naïve patients, sPD-L1 level was negatively correlated with the lymphocyte ratio (correlation coefficient = -0.452, p = 0.014). Kaplan-Meier survival analysis showed that patients with low sPD-L1 level had a significantly longer progression-free survival (PFS) (10.4 vs. 5.7 months, p = 0.023). However, sPD-1 level did not correlate with lymphocyte subsets or prognosis in overall patients with lung cancer. Subgroup analysis showed that prolonged PFS in patients with low sPD-L1 level was exclusively shown in the NSCLC subgroup, not in the SCLC subgroup. In the subgroups of patients who subsequently received immunotherapy, low sPD-L1 level was correlated with longer PFS in the overall patients and NSCLC patients, and low sPD-1 level was correlated with longer PFS exclusively in NSCLC patients.</p><p><strong>Conclusion: </strong>Serum sPD-L1 level was higher in patients with advanced lung cancer than healthy individuals, which was negatively correlated with the proportion of lymphocytes and prognosis. Serum sPD-1 level did not show significant difference between patients with lung cancer and healthy individuals, which showed no correlation with lymphocyte subsets and the prognosis of overall patients, except NSCLC patients receiving immunotherapy.</p>\",\"PeriodicalId\":8633,\"journal\":{\"name\":\"Asia-Pacific journal of clinical oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2025-01-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asia-Pacific journal of clinical oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/ajco.14145\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-Pacific journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajco.14145","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:探讨晚期肺癌患者血清可溶性PD-1 (sPD-1)和可溶性PD-L1 (sPD-L1)水平的变化特点及其与免疫状态和预后的关系。方法:选取2020年7月至2021年11月北京大学人民医院经组织学或细胞学检查诊断为晚期肺癌的患者。记录并分析临床病理资料。按照RESIST 1.1标准评价治疗效果。采用酶联免疫吸附试验(ELISA)检测血清sPD-L1和sPD-1水平。采用流式细胞术检测淋巴细胞亚群,评价患者的免疫状态。结果:共纳入65例晚期肺癌患者。肺癌患者sPD-L1水平(15.67±11.09 pg/mL, p = 0.001)显著高于健康对照组(5.21±4.46 pg/mL)。肺癌患者与健康对照组之间sPD-1水平无显著差异。进展性疾病(PD)患者的sPD-L1水平显著高于部分缓解(PR)患者(20.94±8.91 vs. 13.14±12.66 pg/mL, p = 0.033)。treatment-naïve患者sPD-L1水平与淋巴细胞比例呈负相关(相关系数= -0.452,p = 0.014)。Kaplan-Meier生存分析显示,低sPD-L1水平患者的无进展生存期(PFS)显著延长(10.4个月vs. 5.7个月,p = 0.023)。然而,sPD-1水平与整体肺癌患者的淋巴细胞亚群或预后无关。亚组分析显示,低sPD-L1水平患者的PFS延长只出现在NSCLC亚组,而不出现在SCLC亚组。在随后接受免疫治疗的患者亚组中,低sPD-L1水平与整体患者和非小细胞肺癌患者的PFS延长相关,低sPD-1水平仅与非小细胞肺癌患者的PFS延长相关。结论:晚期肺癌患者血清sPD-L1水平高于健康人群,且与淋巴细胞比例及预后呈负相关。血清sPD-1水平在肺癌患者与健康个体之间无显著差异,与淋巴细胞亚群及整体患者预后无相关性,但接受免疫治疗的非小细胞肺癌患者除外。
Characteristics of Soluble PD-L1 and PD-1 Expression and Their Correlations With Immune Status and Prognosis in Advanced Lung Cancer.
Purpose: Our study aims to evaluate the characteristics of serum soluble PD-1 (sPD-1) and soluble PD-L1 (sPD-L1) levels and their correlations with immune status and prognosis in advanced lung cancer patients.
Methods: Patients diagnosed with advanced lung cancer based on histology or cytology in Peking University People's Hospital from July 2020 to November 2021 were enrolled. Clinicopathological data were recorded and analyzed. Treatment efficacy was evaluated according to RESIST 1.1 criteria. The serum levels of sPD-L1 and sPD-1 were detected by enzyme-linked immunosorbent assay (ELISA). Lymphocyte subsets were measured by flow cytometry to evaluate the immune status of the patients.
Results: A total of 65 patients with advanced lung cancer were enrolled. sPD-L1 level in lung cancer patients (15.67 ± 11.09 pg/mL, p = 0.001) was significantly higher than those in healthy controls (5.21 ± 4.46 pg/mL). sPD-1 level did not show a significant difference between patients with lung cancer and healthy controls. sPD-L1 level in patients with progressive disease (PD) was significantly higher than those with partial response (PR) (20.94 ± 8.91 vs. 13.14 ± 12.66 pg/mL, p = 0.033). In treatment-naïve patients, sPD-L1 level was negatively correlated with the lymphocyte ratio (correlation coefficient = -0.452, p = 0.014). Kaplan-Meier survival analysis showed that patients with low sPD-L1 level had a significantly longer progression-free survival (PFS) (10.4 vs. 5.7 months, p = 0.023). However, sPD-1 level did not correlate with lymphocyte subsets or prognosis in overall patients with lung cancer. Subgroup analysis showed that prolonged PFS in patients with low sPD-L1 level was exclusively shown in the NSCLC subgroup, not in the SCLC subgroup. In the subgroups of patients who subsequently received immunotherapy, low sPD-L1 level was correlated with longer PFS in the overall patients and NSCLC patients, and low sPD-1 level was correlated with longer PFS exclusively in NSCLC patients.
Conclusion: Serum sPD-L1 level was higher in patients with advanced lung cancer than healthy individuals, which was negatively correlated with the proportion of lymphocytes and prognosis. Serum sPD-1 level did not show significant difference between patients with lung cancer and healthy individuals, which showed no correlation with lymphocyte subsets and the prognosis of overall patients, except NSCLC patients receiving immunotherapy.
期刊介绍:
Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.